American College of Emergency Physicians
Clinical Policies Committee Meeting
June 1 – 2, 2020
Zoom Meeting

MINUTES

Participants

Committee members participating in all or part of the meeting: Stephen J. Wolf, MD, FACEP, Chair; Richard Byyny, MD, MSc, FACEP, Methodologist; Stephen V. Cantrill, MD, FACEP, Liaison with Quality & Patient Safety Committee, and to the E-QUAL Steering Committee; Christopher R. Carpenter, MD, MSc, FACEP; Deborah B. Diercks, MD, MSc, FACEP; Seth R. Gemme, MD, FACEP; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Sigrid A. Hahn, MD, MPH; Benjamin W. Hatten, MD, MPH; Jason S. Haukoos, MD, MSc, FACEP, Methodologist; Sean M. Hickey, MD, EMRA Representative; Jon Mark Hirshon, MD, PhD, MPH, FACEP, Board Liaison; Amy Kaji, MD, MPH, PhD, Methodologist; Heemun Kwok, MD, MS, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Devorah J. Nazarian, MD; Susan B. Promes, MD, MBA, FACEP; Kaushal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Scott M. Silvers, MD, FACEP; Michael D. Smith, MD, MBA, FACEP; Molly E.W. Thiessen, MD; Christian A. Tomaszewski, MD, MS, MBA, FACEP; Jonathan H. Valente, MD, FACEP; Stephen P. Wall, MD, MSc, MAEd, Methodologist; Justin Winger, RN, PhD, ENA Representative; Yanling Yu, PhD, Advocate for Patient Safety.

Also present for all or part of the meeting: Mandie Mims, MLS, Staff Liaison; Travis Schulz, MLS, AHIP, Staff Liaison.

Agenda

1. Welcome and Introductions
2. Acute Heart Failure Syndromes Clinical Policy
3. High-Sensitivity Troponin
4. Preliminary Objectives 2020 – 2021
5. Droperidol Policy Statement
6. Subcommittee, Strategic Workgroups, and Liaison Reports
7. Spotlight Report

Major Points Discussed

1. Welcome and introductions

   Dr. Wolf welcomed everyone to the meeting. Participants introduced themselves.

2. Acute Heart Failure Syndromes Clinical Policy

   Dr. Silvers led the discussion on the draft clinical policy. The Committee had a lengthy discussion on the draft. The subcommittee chair will incorporate the edits and the Committee will discuss the revisions on a future Committee call.
3. **High Sensitivity Troponin**

Dr. Wolf and Dr. Promes led the discussion. The Committee discussed the possibility of proposing a new policy statement with accompanying Policy Resource & Education Paper (PREP) on high-sensitivity troponin. The new policy statement will be submitted as part of the Committee’s 2020-2021 objectives and discussed with the Incoming President.

4. **Preliminary Objectives 2020 – 2021**

Dr. Wolf led the discussion. The Committee went over the objectives for the next committee year.

5. **Droperidol Policy Statement**

Dr. Tomaszewski led the discussion. The Committee had a lengthy discussion on the draft. Dr. Tomaszewski will incorporate the edits and the Committee will discuss the revisions on a future Committee call.

6. **Subcommittee, Strategic Workgroups, and Liaison Reports**

Dr. Cantrill (liaison with Quality & Patient Safety Committee and to the E-QUAL Steering Committee) provided a brief report on that Committee’s work.

Dr. Valente (liaison with the Pediatric EM Committee) provided a brief update on that Committee’s work. Dr. Valente also provided an update on the work of the MTBI subcommittee.

Dr. Yu (Advocate for Patient Safety) provided a brief update on her work with the National Quality Forum.

Dr. Carpenter, the co-lead of the Methodologist Workgroup, provided a brief update on the workgroup’s work.

Dr. Lo (liaison with the EQUAL Stroke Workgroup) provided a brief update on that committee’s work. Dr. Lo also provided an update on the work of the Stakeholder Workgroup.

Dr. Hickey provided an update on his work with EMRA.

Dr. Hatten provided updates for the Opioids subcommittee and the Process Workgroup. Dr. Hatten also reported on his liaison work with the American Dental Association and the International Union of Toxicology.

Dr. Shih provided an update on his liaison work with the American Academy of Orthopaedic Surgeons.

Dr. Hahn provided a brief update on the Airway Management subcommittee.

Dr. Silvers provided an update on his liaison work with the American Heart Association.

Dr. Hirshon (Board Liaison) provided an update on his work with the Board.

6. **Subcommittee, Strategic Workgroups, and Liaison Reports (Continued)**
Dr. Godwin provided a brief update on the Airway subcommittee and the Process workgroup.

Dr. Shah provided brief update on the Stakeholder workgroup.

Dr. Tomaszewski (liaison with the Education Committee) provided a brief update on that Committee’s work.

Dr. Smith provided a brief update on the Community-Acquired Pneumonia subcommittee.

Dr. Gerardo provided a brief update on the Blunt Trauma subcommittee.

Dr. Diercks provided a brief update on the Appendicitis subcommittee.

Dr. Winger (ENA representative) gave an update on the current activities of the Emergency Nurses Association.

Drs. Hatten, Mace, Shih, Tomaszewski, and Valente provided updates on their work with the various American College of Radiology appropriateness criteria panels on which they serve.

7. Spotlight Report

Dr. Wolf led an update of the Clinical Policy Spotlight Report.